Predict your next investment

Neovii company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year


About Neovii

Neovii is a biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Neovii Headquarter Location

Zürcherstrasse 19

Rapperswil, 8640,


+41 55 210 05 00

Latest Neovii News

Early second kidney transplantation benefits patients with failing first allograft

Jan 4, 2022

Disclosures: Oberbauer reports receiving research funding from Chiesi, Fresenius, Novartis, Roche and Sandoz; receiving honoraria from Chiesi, Neovii, Sandoz and Teva; patents and inventions with Amgen (sold patent, no royalties); serving as a scientific advisor or member of Amgen, Astellas, Chiesi and Novartis; receiving speaker honoraria from Amgen, Astellas, Chiesi, Fresenius, Novartis and Sandoz; and other interests/relationships with the Austrian Society of Nephrology, the European Society of Nephrology and the European Society of Organ Transplantation. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Early second kidney transplantations correlate with patient survival compared with those waitlisted and on dialysis, according to data published in the Clinical Journal of the American Society of Nephrology. However, the survival difference “diminishes” as patients remain on the waitlist. “At the moment, waiting time for kidney transplant differs between countries and depends on patient-related comorbidities and histocompatibility factors, such as the degree of human leukocyte antigen (HLA) sensitization, HLA genotype and ABO blood group,” Rainer Oberbauer, MD, PhD, from the department of nephrology and dialysis in Internal Medicine III at the Medical University of Vienna, and colleagues wrote. In a retrospective study, researchers used observational data from the Austrian Dialysis and Transplant Registry to assess the way waiting time affects the survival difference of a second kidney transplant patient compared with those waitlisted on dialysis. Researchers followed 2,346 adult participants with a failed first graft who were waitlisted for a second transplant between Jan. 1, 1980, and Aug. 31, 2019, until death, loss to follow-up or end of the observation period. “We used the state-of-the-art causal inference methodology of target trial emulation, which comprised the development of a protocol for a hypothetical randomized trial to answer the research questions of interest, and subsequently using the registry data to mimic the target trial, adhering to the identification principles of causal inference to mitigate biases arising in analyses of observational data,” Oberbauer and colleagues wrote. Mortality served as the primary outcome of this study. Of the 2,346 participants, 1,869 of the waitlisted patients received retransplants and 966 died (262 died while on the waiting list; 704 died after retransplantation). Overall, patients who received a second kidney transplantation gained 5.8 life months by the 10-year follow-up compared with those who remained on the waitlist. However, the survival difference lessened in patients with longer waiting times after loss of the first allograft . Those who waited less than 1 year gained 8 life months, whereas those who waited at least 8 years gained 0.1 life months after the second transplantation. “We conclude that early retransplantation for eligible individuals provides an effective treatment strategy to improve overall survival in patients with a failing first allograft. This survival difference may diminish in patients eligible for transplantation with a waiting time for retransplantation longer than 3 years,” Oberbauer and colleagues wrote. “Our findings could provide further perspectives on allocation priorities as donor organs remain a limited good.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Neovii Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neovii Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.